NYSE:JNJPharmaceuticals
Does Johnson & Johnson’s 2025 Rally Still Offer Value After Strong DCF and PE Signals?
Wondering if Johnson & Johnson is still a buy at around $206 a share, or if the easy gains are already behind it? This breakdown will help you decide whether the current price matches the company’s long term fundamentals.
Despite a recent dip of 3.6% over the last week, the stock is still up 1.2% over the past month, 43.3% year to date and 46.4% over the last year, which indicates the market has been steadily re-rating J&J’s prospects.
That momentum has been shaped by a stream of news, from...